WO2017057851A1 - 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 - Google Patents
진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 Download PDFInfo
- Publication number
- WO2017057851A1 WO2017057851A1 PCT/KR2016/009665 KR2016009665W WO2017057851A1 WO 2017057851 A1 WO2017057851 A1 WO 2017057851A1 KR 2016009665 W KR2016009665 W KR 2016009665W WO 2017057851 A1 WO2017057851 A1 WO 2017057851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- fatty acid
- formula
- ginsenoside
- acid ester
- Prior art date
Links
- 0 CC(CCC=C(C)C)(C(CC1)C(C(C2)O)C1(C)C(C)(CC1*)C2C2(C)C1C(C)(C)C(*)CC2)OC(C(C1O)O)OC(C*)C1O Chemical compound CC(CCC=C(C)C)(C(CC1)C(C(C2)O)C1(C)C(C)(CC1*)C2C2(C)C1C(C)(C)C(*)CC2)OC(C(C1O)O)OC(C*)C1O 0.000 description 1
- GFOGOJHPICMRPG-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(OCC(C(C(C1O)O)O)OC1OC(C)(CCC=C(C)C)C(CC1)C(C(C2)O)C1(C)C(C)(CC1O)C2C(CC2)C1C(C)(C)C2O)=O Chemical compound CCCCCCCCCCCCCCCC(OCC(C(C(C1O)O)O)OC1OC(C)(CCC=C(C)C)C(CC1)C(C(C2)O)C1(C)C(C)(CC1O)C2C(CC2)C1C(C)(C)C2O)=O GFOGOJHPICMRPG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/12—Acting on D ring
- C12P33/16—Acting at 17 position
Definitions
- the present invention relates to a novel ginsenoside fatty acid ester compound having a skin whitening and antioxidant effect, a preparation method thereof, and a cosmetic composition containing the same.
- Ginseng (Panax ginseng CA. Meyer) has been used for the purpose that has been used as a herbal medicine in Korea, China and Japan over 2,000 years ago as a plant belonging to the genus ohgapigwa ginseng, empirically prevent disease and prolong life.
- Ginseng's known effects and effects on the central nervous system, anticarcinogenic and anticancer activity, immune function regulation, antidiabetic activity, hepatic antifungal effect, cardiovascular disorder improvement and anti-arteriosclerosis, blood pressure control, menopause Effects on improving disorders and osteoporosis, antistress and anti-fatigue, antioxidant activity and anti-aging effects are known.
- Ginsenoside a glycoside in ginseng, aka saponin
- 'ginsenoside' a glycoside in ginseng, aka saponin
- Ginsenosides have a structure in which sugar is attached to a steroid skeleton, which is changed by heat. Steaming breaks the steroid-glucose bond, resulting in a drop in sugar and a different effect depending on what sugar remains in the position. As the water-soluble sugars fall, they become fat-soluble and produce ginsenosides that are easy to pass through the cell membrane.
- ginsenoside F1 and ginsenoside compound K have been proposed as active ingredients of the cosmetic composition. These compounds have a structure in which one sugar (glucose) is attached to protopanaxadiol in the saponin component of ginseng.
- Ginsenoside F1 is known to protect human HaCaT keratinocytes by down-regulating the expression of Bcl-2 and Brn-3a from allergy inhibition and apoptosis by irradiation of ultraviolet B. Lee EH, et al ., J. Invest. Dermatol . 121: 607-13, 2003.
- Korean Unexamined Patent Publication No. 2014-0013796 discloses that ginsenoside F1 can be used in cosmetic compositions for improving skin inflammatory diseases by reducing sebum content and improving acne and atopic dermatitis, and Korean Unexamined Patent Publication No. 2013-0095949 Ginsenoside F1 has been suggested to improve the antioxidant, anti-inflammatory and skin moisturizing properties, and is useful as a skin external preparation.
- Korean Patent Nos. 10-0485326 and 10-1427572 disclose that ginsenoside compound K may be applied as an external preparation for skin by promoting the production of hyaluronic acid, and Korean Patent Application Publication No. 2015-0083290 is whitening. And the effect on wrinkle improvement.
- Korean Patent No. 10-1140039 discloses that ginsenoside F1 or compound K can be used as an external preparation for skin because it protects the epidermal dermal boundary of the skin, thereby preventing skin aging and improving wrinkles.
- ginsenoside F1 or compound K may have various effects including skin whitening and antioxidant effects (anti-aging, wrinkle improvement) when applied to cosmetic compositions.
- the skin is structurally composed of lipids, the cell gap and the outermost stratum corneum, the skin surface is covered with sebum (oil component) secreted by the cells.
- sebum oil component
- Ginsenoside F1 or compound K has a structure in which saccharides are connected by ether linkage with alcoholic OH groups, thus having high hydrophilicity and high molecular weight. Therefore, the skin penetrating power of ginsenoside F1 or compound K is very low, and even if a cosmetic composition contains these components, the amount which penetrates or is absorbed by the skin is small, and the effect obtained substantially is inadequate.
- Patent Document 1 Republic of Korea Patent Publication No. 2014-0013796, "Cosmetic composition for improving skin inflammatory diseases comprising ginsenoside F1 as an active ingredient"
- Patent Document 2 Republic of Korea Patent Publication No. 2013-0095949, "External skin composition containing ginsenoside F1"
- Patent Document 3 Republic of Korea Patent No. 10-0485326, "Hyaluronic acid production promoter consisting of ginsenoside compound K"
- Patent Document 4 Republic of Korea Patent No. 10-1427572, "External skin composition for promoting hyaluronic acid production containing ginsenoside Re and ginsenoside compound VII"
- Patent Document 5 Korean Unexamined Patent Publication No. 2015-0083290, "Manufacturing method for ginsenoside derivatives and a composition for whitening and anti-wrinkle comprising ginsenoside derivatives prepared as an active ingredient"
- Patent Document 6 Korean Patent No. 10-1140039, "External Skin Composition Containing Ginsenoside F1 or Compound K"
- Non-Patent Document 1 Lee EH, et al , F1 significantly reduced ultraviolet-B-induced cell death and protected HaCaT cells from apoptosis caused by ultraviolet B irradiation. Ultraviolet-B-induced apoptosis is related with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced down-regulation of Bcl-2 and Brn-3a expression, J. Invest. Dermatol, 121: 607-13, 2003).
- the present inventors reacted with these compounds and fatty acid vinyl ester compounds to increase the hydrophobicity of ginsenoside F1 or compound K, thereby preparing novel compounds.
- the present invention was completed by inhibiting the production of melanin pigment, having a skin whitening effect, and significantly inhibiting the collagen degrading enzyme MMP-1.
- Another object of the present invention is to provide a method for preparing a ginsenoside fatty acid ester compound.
- Still another object of the present invention is to provide a use of the ginsenoside fatty acid ester compound as a cosmetic composition.
- the present invention provides a ginsenoside fatty acid ester compound represented by the following formula (1):
- a method for preparing a ginsenoside fatty acid ester compound of Formula 1 prepared by enzymatic conversion of a compound of Formula 6 and a saturated or unsaturated fatty acid vinyl ester of C12 to C22:
- the present invention also provides a cosmetic composition
- a cosmetic composition comprising the ginsenoside fatty acid ester compound represented by Formula 1 as an active ingredient.
- the ginsenoside fatty acid ester compound according to the present invention has a whitening effect and an anti-wrinkle effect that the existing ginsenoside F1 or compound K has, and hydrophobicity is improved to have excellent skin penetration to the skin keratin.
- the compound acts on tyrosinase, an enzyme that produces melanin pigments causing freckles and blemishes, inhibits the production of melanin pigments, exerts skin whitening effects, and retinophosphate expression of MMP-1, an enzyme that degrades collagen. It can be more significantly suppressed to obtain a wrinkle improvement effect, it is formulated into a variety of cosmetic products to improve the consumer satisfaction.
- Example 1 is a graph showing the MMP-1 inhibitory effect of the compound of Example 1 and Comparative Example 1.
- the present invention proposes a novel compound modified to have hydrophobicity in order to increase the skin absorbency of ginsenoside F1 or compound K.
- the novel compound is a ginsenoside fatty acid ester compound represented by Formula 1:
- R 1 is a C12-C22 saturated or unsaturated fatty acid group
- R 2 is OH or a C12-C22 saturated or unsaturated fatty acid group
- R 3 is H or OH
- Saturated fatty acid groups of C12 to C22 referred to herein are lauryl group (C12: 0, lauryl), tridecyl group (C13: 0, tridecyl), myristyl group (C14: 0, myristil), pentadecyl group (C15 : 0, pentadecyl), palmityl (C16: 0, palmityl).
- Margaryl group (C17: 0, margaryl), stearin group (C18: 0, stearyl), nonadecyl group (C19: 0, nonadecyl), arykidyl group (C20: 0, arachidyl), heneicosyl group (C21: 0 , heneixosylyl), or behenyl group C22: 0, behenyl).
- the unsaturated fatty acid group of C12 to C22 referred to in the present specification is palmitoleyl group (C16: 1, palmitoleyl), oleyl group (C18: 1, oleyl), myrioleyl group (C14: 1 myristoleyl), linoleyl group (C18: 2 linoleyl) or arachidyl group (C20: 3, arachidonyl).
- R 1 is a palmityl group, a stearin group, or an oleyl group, more preferably a palmityl group.
- R 2 to preferably OH, palmityl group, and stearin group, or an oleic group, a palmityl group is OH or more preferably.
- the compounds of formula 1 of the present invention include all isomers unless otherwise specified.
- the isomers can be seen due to all stereoisomers, such as those which may exist due to asymmetric carbons on various R and Z substituents (including enantiomers (which may be present even when no asymmetric carbon is present) and diastereomers) Are considered within the scope of the invention.
- Each stereoisomer of a compound of the invention can be, for example, substantially free of other isomers, or mixed, for example, with racemates or with all stereoisomers or selected stereoisomers.
- Examples of the compound represented by Formula 1 include the following compounds:
- a method for preparing a ginsenoside fatty acid ester compound of Formula 1 by enzymatic conversion of a compound of Formula 6 to a saturated or unsaturated fatty acid vinyl ester of C12 to C22 is provided:
- Such starting materials may be obtained from ginseng, red ginseng, white ginseng, ginseng, rice ginseng, ginseng leaves, or ginseng fruit, or directly manufactured or purchased commercially available.
- ginseng tablet saponin may be hydrolyzed with acid, alkali or enzyme to remove sugar from ginseng saponin, and then the reaction solution may be prepared by passing through a silica column.
- Enzymes that can be used here include beta- glucosidase , alpha, and beta-arabinose degrading enzymes ( ⁇ , ⁇ - arabinosidase ), alpha, and beta-rhamnose degrading enzymes ( ⁇ ) that degrade saponin sugar bonds. and exo-glucose degrading enzymes such as ⁇ - rhamnosidase , and complex enzymes containing them.
- the fatty acid vinyl ester compound is a compound that introduces R 1 and R 2 into the chemical structure of Chemical Formula 1, and may be a C12 to C22 saturated or unsaturated fatty acid vinyl ester compound.
- the C12 to C22 saturated fatty acid vinyl ester compound is a vinyl lauryl ester (C12: 0, lauryl), tridecyl acid vinyl ester (C13: 0, tridecylic acid vinyl ester), myristyl vinyl ester ( C14: 0, myristic acid vinyl ester), pentadecyl acid vinyl ester (C15: 0, pentadecylic acid vinyl ester), palmitic acid vinyl ester (C16: 0).
- Margaric acid vinyl ester (C17: 0, margaric acid vinyl ester), stearic acid vinyl ester (C18: 0, stearic acid vinyl ester), nonadecylic acid vinyl ester (C19: 0, nonadecylic acid vinyl ester), arycydyl acid vinyl ester (C20: 0, arachidyl), heneixosylic acid vinyl ester (C21: 0, hehenixosylic acid vinyl ester), or behenylic acid vinyl ester (C22: 0, behenylic acid vinyl ester).
- the unsaturated fatty acid vinyl ester compounds of C12 to C22 may be palmitoleic acid vinyl ester (C16: 1, palmitoleylic acid vinyl ester), oleic acid vinyl ester (C18: 1, oleylic acid vinyl ester), myrioleic acid vinyl ester (C14: 1 , myristoleylic acid vinyl ester), linoleylic acid vinyl ester (C18: 2), or arachidonylic acid vinyl ester (C20: 3).
- the fatty acid vinyl ester compound is palmitic acid vinyl ester.
- the reaction proceeds with an enzyme conversion reaction.
- the enzyme is a protease (protease) or lipase can be characterized by using a hydrolase, such as (lipase), as the hydrolase is let Plastic Im (flavourzyme), protease A (protease A), Alcala the ( alcalase), Sabina claim (savinase), Pro other Mex (protamex), Esper cyclase (esperase), Novozymes (novozyme), esterase (esterlase), acylase (acylase) and, but to use a mixture thereof, It is not limited to this.
- a microorganism containing the hydrolase may be used as the enzyme source.
- novozyme 435 novozyme 435, Novozyme.
- Such strains may include Bacillus sp, Aspergillus oryzae , Aspergillus niger , Candida antarctica , and mixtures thereof.
- any strain or microorganism containing a hydrolase can be used without limitation.
- reaction temperature is reacted while stirring for 1 to 120 hours, preferably 36 to 72 hours in the range of 20 to 60 °C in the case of novozyme, that is, the enzyme inactivation does not occur.
- the solvent used here is lower alcohols such as water, methanol, ethanol and propanol and acetone, dimethylformamide (DMF), methylene chloride (MC), diisopropyl ether, diethyl ether and tetrahydrofuran (THF) as organic solvents.
- dimethylformamide (DMF) dimethylformamide
- MC methylene chloride
- diisopropyl ether diethyl ether and tetrahydrofuran
- THF tetrahydrofuran
- Dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), chlorobenzene, toluene, benzene and the like can be used alone or in combination, preferably acetone is used.
- the ginsenoside fatty acid ester compound of Formula 1 according to the present invention is applicable to various fields, and may be preferably used as an active ingredient of a cosmetic composition.
- the ginsenoside fatty acid ester compound of Formula 1 exhibits hydrophobicity while maintaining the whitening effect and wrinkle improvement effect of the ginsenoside compound, especially the ginsenoside F1 and the compound K, and is excellent in penetrating power to the stratum corneum.
- the ginsenoside fatty acid ester compound of the present invention exhibits hydrophobicity, the reactivity with tyrosinase, an enzyme that produces melanin pigments causing freckles and blemishes, is improved. For this reason, as shown in the test example 1, the whitening effect excellent compared with the koji-acid or rucinol which was excellent in the conventional whitening effect was secured.
- the ginsenoside fatty acid ester compound of the present invention was significantly inhibited than retinoic acid, thereby ensuring a wrinkle improvement effect. It can be seen that.
- the ginsenoside fatty acid ester compound of Formula 1 may be used as an active ingredient of the cosmetic composition, the content of which varies depending on the formulation, it may be used in 0.001 to 99% by weight.
- the active ingredient is contained in the above range, it is not only suitable to exhibit the intended effect of the present invention, but also satisfies both the stability and solubility of the composition, and may be appropriate to include in the above range in terms of cost-effectiveness.
- Cosmetic compositions can be prepared in any formulations conventionally prepared in the art, including, for example, solution suspensions, emulsions, pastes, gels, creams, lotions, powders, oils, powder foundations, emulsion foundations, wax foundations And it may be formulated in a spray or the like, but is not limited thereto. More specifically, it may be prepared in the form of a sun cream, a flexible lotion, a convergent lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a pack, a spray or a powder.
- the cosmetic composition according to the present invention is a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic type or Nonionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatology field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
- the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. .
- the formulation is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, especially in the case of a spray, additionally chlorofluorohydrocarbon, propane / butane.
- propellants such as dimethyl ether.
- a solvent, solubilizer or emulsion is used as carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 Fatty acid esters of butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- a carrier diluent such as water, ethanol or propylene glycol
- suspending agents such as ethoxylated isostearin alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, Aluminum metahydroxide, bentonite, agar or tracant and the like can be used.
- Pressure tube (Compound K, 1eq), vinyl palmitate (2.5eq), 42.5 molecular sieve (100 wt%), novozyme 435, and anhydrous acetone (500 wt%, 5 to substrate) Pear) was injected and stirred at 45 ° C. for 3 days to proceed with the reaction.
- a compound of Chemical Formula 3 (yield 85%) was prepared in the same manner as in Example 1, except that the compound of Chemical Formula 7 (ginsenoside F1, 1 eq) was used as a starting material.
- a compound of Chemical Formula 4 (yield 89%) was prepared in the same manner as in Example 1, except that the compound of Chemical Formula 8 (Compound K, 2eq) was used as a starting material.
- a compound of Formula 5 was prepared (yield 88%) in the same manner as in Example 1, except that the compound of Formula 7 (ginsenoside F1, 2eq) was used as a starting material.
- the melanin production inhibitory effect in melanocyte-producing cells to the compound prepared in Example 2 was measured by Dooley's method.
- the cell line used mouse-derived B16 F10 (melanoma cells) purchased from Korea Cell Line Bank.
- DMEM (Cat No. 11995)
- FBS (Cat No. 16000-044)
- antibiotic-antifungal reagents (Cat No. 15240-062) required for cell culture were purchased from Invitrogen (GIBCO).
- Example (IC 50 ) concentration of Example (IC 50 ) required to reduce melanin production in melanocytes by half is calculated and shown in the table below.
- the ginsenoside fatty acid ester compound according to the present invention can inhibit melanin production in a small amount compared to koji acid and rucinol. Therefore, it can be seen that the ginsenoside fatty acid ester compounds according to the present invention have excellent skin whitening effect by inhibiting melanin production.
- fibroblasts were dispensed in four well plates at 1 ⁇ 10 4 per well, containing 10% FBS until reaching about 80% confluency. Incubated for about 24 hours in the medium. Thereafter, the cells were exchanged with a medium without FBS for 24 hours.
- UVB 15 mJ / cm2 was irradiated with 100 ml of PBS. After PBS was removed, the resultant was treated by diluting the final concentration of the ginsenoside fatty acid ester compound prepared in Example 2 to 0.01, 0.05, 0.1 and 0.5% in a fresh medium without FBS. Retinoic acid was used. After 48 hours of treatment with the test substance, the culture supernatant was collected and evaluated for expression of MMP-1 using ELISA kits (enzyme-linked immunosorbent assay kits; RPN 2610, Biotrak Amersham Pharmacia Biotech, UK). The amount of MMP-1 respectively measured was corrected by the total protein amount, and the results are shown in Table 2 and FIG. 1. 1 is a graph comparing the MMP-1 inhibition rate of the compound of Example 1 and Comparative Example 1
- Example 1 Example 2
- Example 3 Example 4 Comparative Example 1 0 100 100 100 100 100 100 0.01 97.9 97 97.1 97.5 98.1 0.05 77.1 75.1 79.5 80.1 87.3 0.1 64.3 65.5 63.4 66.7 82.5 0.5 40.7 42.5 43.2 45.5 72.2
- the ginsenoside fatty acid ester compound according to the present invention than the retinoic acid of Comparative Example 1 It can be seen that it significantly inhibits the expression of MMP-1.
- the ginsenoside fatty acid ester compound presented in the present invention inhibits the biosynthesis of the skin tissue degrading enzyme MMP-1 generated by internal aging or external environmental factors, thereby inhibiting skin aging and improving wrinkles. It can be seen.
- the cosmetic formulation containing the ginsenoside fatty acid ester compound according to the present invention is not limited only to these examples.
- the lotion was prepared according to a conventional method with the composition described in the table below.
- a nutritious cream was prepared according to a conventional method with the composition described in the table below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
시험 물질 | IC50 |
코지산 | >500 μM |
루시놀 | 16 μM |
실시예 1의 화합물 | 7.8 μM |
실시예 2의 화합물 | 7.2 μM |
실시예 3의 화합물 | 7.5 μM |
실시예 4의 화합물 | 7.4 μM |
농도(%) | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 비교예 1 |
0 | 100 | 100 | 100 | 100 | 100 |
0.01 | 97.9 | 97 | 97.1 | 97.5 | 98.1 |
0.05 | 77.1 | 75.1 | 79.5 | 80.1 | 87.3 |
0.1 | 64.3 | 65.5 | 63.4 | 66.7 | 82.5 |
0.5 | 40.7 | 42.5 | 43.2 | 45.5 | 72.2 |
성분 | 함량(중량%) |
실시예 1의 화합물 | 0.1 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
PEG 12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 1의 화합물 | 2.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올리에이트 | 0.5 |
PEG 60 경화피마자유 | 2.0 |
유동파라핀 | 10. |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 1의 화합물 | 1.0 |
밀납 | 10.0 |
폴리솔베이트 60 | 1.5 |
PEG 60 경화피마자유 | 2.0 |
솔비탄세스퀴올레이트 | 0.8 |
유동파라핀 | 40.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 4.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 1의 화합물 | 0.2 |
폴리비닐알콜 | 13.0 |
소듐카르복시메틸셀룰로오스 | 0.2 |
글리세린 | 5.0 |
알란토인 | 0.1 |
에탄올 | 6.0 |
PEG 12 노닐페닐에테르 | 0.3 |
폴리솔베이트 60 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
Claims (7)
- 제1항에 있어서,상기 R1은 라우릴기, 트라이데실기, 미리스틸기, 펜타데실기, 팔미틸기, 마르가릴기, 스테아린기, 노나데실기, 아리키딜기, 헤네이코실기, 베헤닐기, 팔미트올레일기, 올레일기, 미리스올레일기, 리놀레일기, 또는 아라키도닐기이고,상기 R2는 OH, 라우릴기, 트라이데실기, 미리스틸기, 펜타데실기, 팔미틸기, 마르가릴기, 스테아린기, 노나데실기, 아리키딜기, 헤네이코실기, 베헤닐기, 팔미트올레일기, 올레일기, 미리스올레일기, 리놀레일기, 또는 아라키도닐기이고,상기 R3는 H 또는 OH인 것을 특징으로 하는 진세노사이드 지방산 에스터 화합물.
- 제4항에 있어서,상기 R1은 라우릴기, 트라이데실기, 미리스틸기, 펜타데실기, 팔미틸기, 마르가릴기, 스테아린기, 노나데실기, 아리키딜기, 헤네이코실기, 베헤닐기, 팔미트올레일기, 올레일기, 미리스올레일기, 리놀레일기, 또는 아라키도닐기이고,상기 R2는 OH, 라우릴기, 트라이데실기, 미리스틸기, 펜타데실기, 팔미틸기, 마르가릴기, 스테아린기, 노나데실기, 아리키딜기, 헤네이코실기, 베헤닐기, 팔미트올레일기, 올레일기, 미리스올레일기, 리놀레일기, 또는 아라키도닐기이고,상기 R3는 H 또는 OH인 것을 특징으로 하는 진세노사이드 지방산 에스터 화합물의 제조방법.
- 제4항에 있어서,상기 효소 전환 반응은 플라보자임(flavourzyme), 프로테아제 A(protease A), 알칼라제(alcalase), 사비나제(savinase), 프로타멕스(protamex), 에스퍼라제(esperase), 노보자임(novozyme), 에스테라제(esterlase) 및 아실라제(acylase)로 이루어진 군에서 선택된 1종 이상의 효소를 이용하는 것을 특징으로 하는 진세노사이드 지방산 에스터 화합물의 제조방법.
- 제1항 내지 제3항 중 어느 한 항에 따른 진세노사이드 지방산 에스터 화합물을 유효성분으로 포함하는 것을 특징으로 하는 화장료 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680052641.9A CN108137640B (zh) | 2015-09-30 | 2016-08-30 | 人参皂苷脂肪酸酯类化合物、其制备方法以及含有其的化妆品组合物 |
MYPI2018700435A MY184483A (en) | 2015-09-30 | 2016-08-30 | Ginsenoside fatty acid ester compound, method for preparing same, and cosmetic composition comprising same |
AU2016332770A AU2016332770B2 (en) | 2015-09-30 | 2016-08-30 | Ginsenoside fatty acid ester compound, method for preparing same, and cosmetic composition comprising same |
SG11201800961YA SG11201800961YA (en) | 2015-09-30 | 2016-08-30 | Ginsenoside fatty acid ester compound, method for preparing same, and cosmetic composition comprising same |
HK18114992.9A HK1255926A1 (zh) | 2015-09-30 | 2018-11-23 | 人參皂苷脂肪酸酯類化合物、其製備方法以及含有其的化妝品組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150137302A KR102029040B1 (ko) | 2015-09-30 | 2015-09-30 | 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 |
KR10-2015-0137302 | 2015-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017057851A1 true WO2017057851A1 (ko) | 2017-04-06 |
Family
ID=58427808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/009665 WO2017057851A1 (ko) | 2015-09-30 | 2016-08-30 | 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 |
Country Status (8)
Country | Link |
---|---|
KR (1) | KR102029040B1 (ko) |
CN (1) | CN108137640B (ko) |
AU (1) | AU2016332770B2 (ko) |
HK (1) | HK1255926A1 (ko) |
MY (1) | MY184483A (ko) |
SG (1) | SG11201800961YA (ko) |
TW (1) | TWI717385B (ko) |
WO (1) | WO2017057851A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467358B (zh) * | 2020-03-31 | 2021-05-14 | 陕西巨子生物技术有限公司 | 包含人参皂苷Rh3、PPD和Rh2的药物组合物 |
KR102430732B1 (ko) | 2021-10-18 | 2022-08-10 | (주)디아이지엔지니어링건축사사무소 | 토목 및 건축 하중지지 영구 흙막이벽 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594341A (zh) * | 2004-06-28 | 2005-03-16 | 吉林农业大学 | 人参皂苷次级苷compound K的脂肪酸酯类化合物及制备方法 |
CN1651452A (zh) * | 2004-12-01 | 2005-08-10 | 大连大学 | 人参皂苷次级苷脂肪酸酯类化合物,其制备方法和以该化合物为活性成分的药物组合物 |
KR20100116051A (ko) * | 2009-04-21 | 2010-10-29 | 한밭대학교 산학협력단 | 리파아제를 이용한 진세노사이드 지방산 에스터 화합물의 제조 방법 |
CN101880305A (zh) * | 2010-06-23 | 2010-11-10 | 大连大学 | 人参皂苷代谢物m1脂肪酸酯类化合物的制备方法 |
KR20130115455A (ko) * | 2012-04-12 | 2013-10-22 | (주) 비엔씨바이오팜 | 미백 및 주름 개선용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100485326B1 (ko) | 2002-12-26 | 2005-04-27 | 주식회사 태평양 | 진세노사이드 화합물 k로 이루어진 히알루론산 생성촉진제 |
KR101140039B1 (ko) | 2004-01-26 | 2012-05-02 | (주)아모레퍼시픽 | 진세노사이드 f1 또는 화합물 k를 함유하는 피부외용제조성물 |
KR101427572B1 (ko) | 2009-11-25 | 2014-08-08 | (주)아모레퍼시픽 | 진세노사이드 Re 및 진세노사이드 화합물 K를 함유하는 히알루론산 생성 촉진용 피부 외용제 조성물 |
CN102603847A (zh) * | 2010-11-18 | 2012-07-25 | 吉林农业大学 | 人参皂苷Rh2脂肪酸酯类化合物制备方法及其医药用途 |
CN102600189A (zh) * | 2011-01-24 | 2012-07-25 | 吉林农业大学 | 人参次级皂苷及其脂肪酸酯衍生物在糖尿病中的应用 |
KR101909533B1 (ko) | 2012-02-21 | 2018-10-19 | (주)아모레퍼시픽 | 진세노사이드 f1을 함유하는 피부 외용제 조성물 |
KR20140013796A (ko) | 2012-07-27 | 2014-02-05 | 강원대학교산학협력단 | 진세노사이드 f1을 유효 성분으로 포함하는 피부 염증질환 개선용 화장료 조성물 |
KR101569089B1 (ko) | 2014-01-09 | 2015-11-13 | 경희대학교 산학협력단 | 진세노사이드 유도체의 제조방법 및 이에 의해 제조된 진세노사이드 유도체를 유효성분으로 포함하는 미백 및 주름개선용 조성물 |
-
2015
- 2015-09-30 KR KR1020150137302A patent/KR102029040B1/ko active IP Right Grant
-
2016
- 2016-08-30 AU AU2016332770A patent/AU2016332770B2/en not_active Ceased
- 2016-08-30 SG SG11201800961YA patent/SG11201800961YA/en unknown
- 2016-08-30 CN CN201680052641.9A patent/CN108137640B/zh active Active
- 2016-08-30 MY MYPI2018700435A patent/MY184483A/en unknown
- 2016-08-30 WO PCT/KR2016/009665 patent/WO2017057851A1/ko active Application Filing
- 2016-09-19 TW TW105130087A patent/TWI717385B/zh not_active IP Right Cessation
-
2018
- 2018-11-23 HK HK18114992.9A patent/HK1255926A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594341A (zh) * | 2004-06-28 | 2005-03-16 | 吉林农业大学 | 人参皂苷次级苷compound K的脂肪酸酯类化合物及制备方法 |
CN1651452A (zh) * | 2004-12-01 | 2005-08-10 | 大连大学 | 人参皂苷次级苷脂肪酸酯类化合物,其制备方法和以该化合物为活性成分的药物组合物 |
KR20100116051A (ko) * | 2009-04-21 | 2010-10-29 | 한밭대학교 산학협력단 | 리파아제를 이용한 진세노사이드 지방산 에스터 화합물의 제조 방법 |
CN101880305A (zh) * | 2010-06-23 | 2010-11-10 | 大连大学 | 人参皂苷代谢物m1脂肪酸酯类化合物的制备方法 |
KR20130115455A (ko) * | 2012-04-12 | 2013-10-22 | (주) 비엔씨바이오팜 | 미백 및 주름 개선용 조성물 |
Non-Patent Citations (1)
Title |
---|
LEI, J. ET AL.: "Isoation, Synthesis and Structures of Cylotoxic Ginsenoside Derivatives", MOLECULES, vol. 12, no. 9, 2007, pages 2140 - 2150, XP055208082 * |
Also Published As
Publication number | Publication date |
---|---|
TW201717903A (zh) | 2017-06-01 |
MY184483A (en) | 2021-04-01 |
TWI717385B (zh) | 2021-02-01 |
KR20170038234A (ko) | 2017-04-07 |
HK1255926A1 (zh) | 2019-09-06 |
AU2016332770A1 (en) | 2018-01-25 |
CN108137640B (zh) | 2021-09-07 |
AU2016332770B2 (en) | 2020-08-06 |
KR102029040B1 (ko) | 2019-10-07 |
SG11201800961YA (en) | 2018-03-28 |
CN108137640A (zh) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014116022A1 (ko) | 레스베라트롤 유도체의 피부미백 용도 | |
WO2019045259A2 (ko) | 철피석곡 꽃 추출물을 포함하는 화장료 조성물 | |
WO2015099274A1 (ko) | 탈분화 식물 프로토플라스트 내에 활성 물질이 인입된 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
WO2017026855A1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 피부상태 개선용 조성물 | |
WO2018164369A1 (ko) | 효소 처리된 무궁화 추출물을 유효성분으로 함유하는 피부 주름 개선용 조성물 | |
WO2024049120A1 (ko) | 친환경 천연 공융 용매로 추출한 추출물을 포함하는 화장료 조성물 | |
WO2020246766A1 (ko) | 찹쌀떡버섯으로 발효한 홍경천 추출물을 함유하는 피부노화 예방 또는 개선용 조성물 | |
WO2017057851A1 (ko) | 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
WO2016159580A1 (ko) | 티아사포제놀 유도체를 유효성분으로 포함하는 조성물 | |
WO2018066914A1 (ko) | 지방산이 결합된 트리펩타이드 및 이를 포함하는 주름 개선용 화장료 조성물 | |
WO2019088402A1 (ko) | 뷔베리신 또는 뷔베리신 유도체를 유효성분으로 포함하는 피부 미백용 조성물 | |
WO2017057852A1 (ko) | 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
WO2018080166A2 (ko) | 3,4,5-트리메톡시 신남산 에스테르 유도체와 그 제조방법 및 이를 포함하는 피부 미백용 조성물 | |
WO2020096379A1 (ko) | 아우레오바시디움 풀루란스 균주의 배양물 또는 추출물을 포함하는 저자극 피부 재생 또는 피부 진정용 조성물 | |
WO2016159640A2 (ko) | 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물 | |
WO2016137196A1 (ko) | 지방산 컨쥬게이션된 7-데하이드로콜레스테롤 유도체 | |
WO2016093515A1 (ko) | 장수 유전자 활성화용 조성물 | |
WO2010114305A2 (ko) | 페길레이션된 베튤린 유도체 및 그를 포함하는 화장료 조성물 | |
WO2019031790A1 (ko) | 세라마이드, 이의 유도체 및 목근피 추출물을 함유하는 피부 외용제 조성물 | |
WO2014157910A1 (ko) | 효소처리 타나까 추출물을 함유하는 조성물 | |
WO2012173383A2 (ko) | 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 | |
WO2021095966A1 (ko) | 클로렐라 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물 | |
WO2021075929A1 (ko) | 애엽 추출물을 포함하는 피부 손상 개선용 조성물 | |
WO2018151563A1 (ko) | 코스모스 추출물을 포함하는 광노화 방지 및 피부주름 개선용 조성물 | |
WO2013070018A1 (ko) | 카르노스산 또는 그 유도체를 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16851998 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016332770 Country of ref document: AU Date of ref document: 20160830 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201800961Y Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16851998 Country of ref document: EP Kind code of ref document: A1 |